一级日本牲交大片好爽在线看,18禁裸乳无遮挡自慰直播网站,自拍偷区亚洲网友综合图片,看骚逼Tv,Com,天天干天天屌天天草,五月激情六月丁香,欧美熟妇vdeoslisa18

Study reveals clues to improve cancer immunotherapy

Source: Xinhua| 2019-10-25 03:34:59|Editor: ZX
Video PlayerClose

CHICAGO, Oct. 24 (Xinhua) -- A study by researchers at Washington University School of Medicine in St. Louis suggests that recruiting other T cells, called helper T cells, besides killer T cells could boost the effectiveness of immune therapy, as helper T cells are involved in recognizing cancer as a threat and recruiting killer T cells to mount an attack.

Studying mice with models of human cancer, the researchers showed that immune checkpoint therapy is more effective when helper T cells are activated along with killer T cells. They further showed that vaccines also are more effective when targets activating both helper and killer T cells are present.

"Just because a killer T cell is present doesn't mean it's actively killing tumor cells," said first author Elise Alspach, a postdoctoral research associate at the university. "We found that not only do you need helper T cells to recruit the killer T cells, the helper cells need to be there to coax the killer T cells to mature into an active state in which they are capable of killing cells."

And finally, the most effective anti-tumor responses occurred when immune checkpoint therapy was combined with a vaccine that incorporates targets for helper and killer T cells that are specific to antigens in the patient's tumor.

The researchers have developed a computer program that can predict which mutant proteins, or antigens, on a patient's tumor will specifically activate helper T cells.

"The idea of giving checkpoint inhibitors along with a tumor-specific vaccine, especially a vaccine that activates both killer and helper T cells, is just beginning," said senior author Robert D. Schreiber, a distinguished professor at the university. "But based on our study, the combination is likely to be more effective than any of the components alone. Today, when we treat a particular tumor type with checkpoint inhibitors, maybe 20 percent of the patients respond well. We're hoping that with a vaccine plus checkpoint inhibitors, the number of patients who respond well will go up to 60 or 70 percent."

The study was published on Wednesday in the journal Nature.

TOP STORIES
EDITOR’S CHOICE
MOST VIEWED
EXPLORE XINHUANET
010020070750000000000000011100001385003601